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for the MRIdian plans. The mean results and the standard 
deviations are summarized in the table. 
 
 
 
Conclusion: A comparable PTV dose coverage between the 3 
plans was found for rectal cancer, with a HI advantage for 
the PTV1 for the MRIdian plan. Differences were described 
for OaRs, especially for low dose areas (V5 Body). MRIdian 
allowed to reach dosimetrical goals comparable to RapidArc 
and IMRT gold standards. The evaluation of a possible 
reduction in PTV margin and a proper target coverage by MRI 
based gating will be analyzed when the system will become 
operative at Gemelli ART.  
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Purpose or Objective: The cervix-uterus shows large day-to-
day variation in position and size, mainly depending on 
bladder and rectum filling. Image-guided adaptive 
radiotherapy with a library of plans (LOP) is a strategy to 
mitigate these large variations, resulting in less dose to 
organs at risk (OAR) compared to the use of a single plan with 
a population-based PTV margin. A further reduction of OAR 
dose can be achieved using proton therapy. However, it is 
challenging to achieve a target coverage that is robust for 
range and position uncertainties. The aim of this study is to 
compare target coverage of robustly optimized photon and 
proton therapy plans using a LOP adaptive strategy for 
cervical cancer. 
 
Material and Methods: Five cervical cancer patients treated 
with photon therapy were retrospectively included. For each 
patient a full and empty bladder planning CT and weekly 
repeat CTs were acquired. Depending on the magnitude of 
cervix-uterus motion, one to three ITV sub ranges were 
generated by interpolation of the CTV delineations on full 
and empty bladder CT. Target and OARs were delineated on 
all repeat CTs. Robustly optimized photon (VMAT) library 
plans and proton (IMPT) library plans were generated with a 
prescribed dose of 46 Gy in 23 fractions to the ITV. For robust 
optimization, a position uncertainty of 0.8 cm was applied; 
for protons 3% range uncertainty was included as well. The 
plans were required to have sufficient target coverage 
(V95%>99%) for both the nominal scenario and twelve 
scenarios with different range and position errors. Both for 
protons and photons the actual delivered dose was simulated. 
Repeat CTs were registered to the full bladder planning CT 
using bony anatomy, the best fitting library plan was selected 
and the dose was recalculated. The DVH for the whole 
treatment was estimated by adding and scaling DVHs. The 
target coverage was evaluated for the total CTV as well as 
the CTVs of the corpus uteri, cervix, vagina and elective 
lymph nodes. 
 
Results: For the total CTV, on average, the V95% for the 
whole treatment was 99.9% (range 97.3%-99.8%) for photons 
and 96.3% (93.5%-98.1%) for protons. The V95% of the corpus 
uteri was 95.7% (86.3%-99.9%) and 88.7% (68.4%-99.9%) for 
photons and protons, respectively. Figure 1 shows a repeat 
CT with insufficient target coverage both for photons and 
protons. The elective lymph nodes received sufficient dose 
with photons, on average, V95% was 99.1% (98.1%-99.8%). 
With protons this volume decreased to 96.2%(94.9%-98.8%). 
For the cervix and vagina no differences between the use of 
photons and protons were observed. 
 
 
 
Conclusion: The robustly optimized proton therapy plans did 
not result in an adequate target coverage for all patients for 
the realistic robustness parameters used. For some cases the 
used LOP strategy is not sufficient to cope with the large 
movements of the cervix-uterus for both modalities. The 
impact of underdosing is larger using protons than using 
photons. 
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Purpose or Objective: Dose calculation is currently based on 
the density map provided by CT. However, for delineation of 
the prostate gland and organs at risk T2-weighted MR imaging 
is the gold standard. Dose calculation based on MR 
information would remove the need for a CT scan and avoid 
the uncertainty related to registration of the images. Pseudo-
CT generation from MR scans has recently become available. 
This study investigates the validity of dose calculation based 
on pseudo CT created with commercial software (MR for 
Calculating ATtenuation – MRCAT) compared to standard CT 
based dose calculation. 
 
Material and Methods: Seven high risk prostate cancer 
patients were MR and CT scanned. The clinical, curatively 
intended treatment (78 Gy in 39 Fx) using single arc VMAT 
was based on the conventional CT. From the MR scan pseudo-
CT were created using MRCAT (Philips, Helsinki, Finland). To 
eliminate dose comparison uncertainties related to patient 
positioning differences between CT and MR rigid CT-MR 
